HIV/AIDS HAART
Enfuvirtide once-daily dose bioequivalent to twice-daily dose but has lower antiviral activity
Published in AIDS Weekly, April 24th, 2006
In a recently published article, scientists in the United States conducted an open-label, randomized, multiple dose, two-period crossover study to compare the "pharmacokinetics, safety/tolerability and antiviral activity" of once-daily 180 mg enfuvirtide versus twice daily 90 mg enfuvirtide.
"Steady-state intensive pharmacokinetic samples were obtained on days 7 and 14. Thirty-seven subjects received at least one dose of enfuvirtide. Thirty-three subjects completed both dosing periods," researchers said.
According to M....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-04-24)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
HIV infection inhibited by soluble mimic of globotriaosyl ceramide analogue - HIV/AIDS Prognostic Indicators
Statistical model predicts HAART response from RT and protease amino acid sequence data - HIV/AIDS Transmission
Foreskin inner mucosal surface has cells that make it highly susceptible to HIV - HIV/AIDS Transmission
HIV-1 susceptibility may be influenced by DC-SIGN-related molecule polymorphisms - Cervical Cancer
Reports add new data to cervical cancer research - Condylomata Acuminata
Pegylated IFN alfa-2b safe and effective for HIV-related condylomata acuminata - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
